Fentanyl (IV — Anaesthesia/ICU)
Brand names: Sublimaze
Fentanyl is a potent synthetic opioid used intravenously in anaesthesia and intensive care and, as transdermal patches, for stable chronic severe pain; it is a controlled drug.
Adult dose
Paediatric dose
Dose adjustments
In patients with renal impairment, reduced dosing of fentanyl should be considered and these patients should be observed carefully for signs of fentanyl toxicity.
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
US labelling (FDA)
Reference — US labelling, may differ from UK• Fentanyl Citrate Injection should be administered only by persons specifically trained in the use of intravenous anesthetics and management of the respiratory effects of potent opioids. • Ensure that an opioid antagonist, resuscitative and intubation equipment, and oxygen are readily available ( 2.1 ). • Individualize dosing based on the factors such as age, body weight, physical status, underlying pathological condition, use of other drugs, type of anesthesia to be used, and the surgical procedure involved. ( 2.1 ) • Initiate treatment in adults with 50 mcg to 100 mcg. ( 2.2 ) • Initiate treatment in children 2 to 12 years of age, with a reduced dose as low as 2 mcg/kg to 3 mcg/kg. ( 2.2 …
Source: US FDA prescribing information (openFDA / DailyMed), label dated 2025-09-24. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.
Contraindications
- Hypersensitivity to the active substance, to any of the excipients, or to other opioids
- Respiratory depression; obstructive airways disease
- Concurrent administration with monoamine oxidase inhibitors, or within 2 weeks of their discontinuation
Side effects
- Nausea (26.1%) and vomiting (18.6%)
- Muscle rigidity, which may also involve the thoracic muscles (10.4%)
- Hypotension (8.8%) and hypertension (8.8%)
- Bradycardia (6.1%); also tachycardia and arrhythmia
- Sedation (5.3%); dizziness, dyskinesia
- Respiratory depression, apnoea, laryngospasm and bronchospasm; drug withdrawal syndrome and drug dependence
Interactions
- Monoamine oxidase inhibitors — concurrent use, or use within 2 weeks of discontinuation, is contraindicated (UK SPC section 4.3; the eMC bundle did not include section 4.5)
- CYP3A4 inhibitors (examples given: macrolide antibiotics such as erythromycin, azole antifungals such as ketoconazole, protease inhibitors) can increase fentanyl plasma concentration, causing increased or prolonged opioid effects — if concomitant use is necessary consider dosage reduction and monitor frequently for respiratory depression and sedation; on stopping the inhibitor, fentanyl concentrations fall, risking reduced efficacy or withdrawal in physically dependent patients (US label section 7)
- Chemically incompatible in the same line with the induction agents pentobarbital sodium, thiopentone and methohexitone (UK SPC sections 4.2 and 6.2)
- When a neuroleptic is used with fentanyl, chills and/or shivering, restlessness, postoperative hallucinatory episodes and extrapyramidal symptoms may be observed
Clinical monograph
How it works
It is a potent mu-opioid receptor agonist with rapid onset given intravenously.
Prescribing in practice
- It is many times more potent than morphine, so dosing errors are dangerous; transdermal patches are only for opioid-tolerant patients with stable pain, not for acute or opioid-naive use.
- Heat increases absorption from patches (fever or external heat) and can cause overdose.
- Respiratory depression is the main risk; it causes less histamine release and is often preferred in haemodynamic instability or renal impairment.
Monitoring
Monitor respiratory rate, sedation and pain; with patches review at each change.
Counselling the patient
- With a patch, avoid heat (hot baths, heat pads) over it and follow the change schedule.
- Report excessive drowsiness or slow breathing.
- Dispose of used patches safely — they still contain drug.
Evidence & guidelines
A potent opioid for anaesthesia and intensive care and, as patches, for stable chronic severe pain in opioid-tolerant patients.
Reference: FICM Guidelines on Analgesia/Sedation in ICU; Stoelting's Pharmacology; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Modified Mallampati Classification · Airway Assessment
- Aldrete Score for Post-Anaesthesia Discharge · Post-operative
- Morphine Milligram Equivalents (MME) Calculator · Pain / Opioids
- Opioid Conversion / Equianalgesic Guide · Pain Management
- Mallampati Score (Airway Assessment) · Airway Assessment
- ASA Physical Status Classification · Perioperative Risk